cabozantinib,nivolumab,ipilimumab
exelixis,bms
['triplet,(-triplete)', 'rcc,(-irccs),(-srcc),(-urcc)', 'cosmic313']
#esmo22 #cosmic313: longer pfs with triplet vs doublet. mpfs nr vs 11.3 mo with benefit seen in most predefined subgroups #rcc 
CME experts Sara Fagerlie, PhD, CHCP & Mindy Tanzola, PhD have joined forces at Front Row to help clinicians & educators manage the oncology information deluge